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ABSTRACT 
Hepatitis B and hepatitis C virus infection are common in Nigeria; where they are a major cause of both acute and chronic 
liver disease, as well as hepatocellular cancer. Persons at risk of acquisition of Human Immunodeficiency Virus (HIV) 
infection are also at risk of acquisition of infection with Hepatitis B virus (HBV) and Hepatitis C virus (HCV). We set out to 
determine the epidemiology of HBV and HCV infection among HIV Counseling and Testing (HCT) clients at the Jos 
University Teaching Hospital (JUTH), Nigeria.  
This was a cross-sectional study conducted at the HCT unit of the AIDS Prevention Initiative in Nigeria (APIN) Jos 
University Teaching Hospital (JUTH), Jos, Nigeria between November, 2012 and April 2013.  
Subjects were recruited consecutively at the HCT unit of APIN JUTH. Included were subjects 18 years of age and above, 
antiretroviral (ARV) drug naive, who accepted and signed the consent form.Clients who declined to sign the consent form 
were excluded. The study involved collecting demographic data, exposure to risk factors and laboratory determination of 
HBV and HCV sero-prevalence in the subjects using Enzyme Linked Immunoassay (ELISA) and Polymerase chain reaction 
(PCR) assay methods.  
Chi-squared test was used to determine significance of association between categorical variables.  
One hundred and thirty two (56.9%) were females, 100 (43.1%) were males. Thirty six (15.5%) tested positive for HBsAg by 
ELISA, 31 (13.4%) were confirmed positive by DNA PCR. Nine (3.9%) tested positive by ELISA to HCV antibody, 7 (3.0%) 
were confirmed positive by RNA PCR. Co-infection rate of HIV / HBV was 5.2%. Infection was more common among those 
younger than 36 years in the case of HBV and those older than 36 years in the case of HCV.We concluded the prevalence of 
HBV infection was high. Study was limited by the cross sectional design. 
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RESUME  
Les infections de virus de l’hépatite B et C sont communs au Nigeria ; où ils sont une cause majeure de la maladie de foie 
aiguë et chronique ainsi que le cancer hépatocellulaire. Les personnes à risque d’acquisition d’infection de virus 
d’immunodéficience humaine (VIH) sont aussi à risque d’acquisition de l’infection par le virus de l’hépatite B(VHB) et 
hépatite C(VHC). Nous avons cherché a déterminer l’épidémiologie de l’infection par VHB et VHC parmi les clients de 
VIH en consultation et au dépistage (HCT) a l’université hôpital d’enseignement de Jos(JUTH), Nigeria. 
C’était une étude transversale menée a l’unité de HCT de l’Initiative de la prévention du SIDA au Nigeria (APIN) a 
l’’Universite hôpital d’enseignement de Jos (JUTH) , Jos, Nigeria entre novembre 2012 et avril 2013. 
Les sujets ont été recrutés consécutivement a l’unité de HCT de APIN JUTH. Inclus étaient des sujets de dix – huit ans au – 
dessus, antirétroviral naïve (ARV), qui ont acceptée et signé le formulaire de consentement. Les clients qui ont refusé a 
signer le formulaire de consentement ont été exclus. L’étude a impliqué recueillir de données démographiques, l’exposition 
aux facteurs de risques et la détermination en laboratoire du VHB et VHC en utilisant dosage immuno – enzymatique lie 
(ELISA) et les méthodes d’essai de réaction en chaine de la Polymérase (PCR). Chi – squared test a été utilisé pour 
déterminer l’importance de l’association ente les variables catégoriques. Cent trente – deux (56,9%) étaient femelles, 
100(43,1%), étaient males. Trente – six(15,5%) ont été testés positifs pour HBsAg par ELISA, 31 (13,4%) ont été confirmés 
positifs par DNA PCR. Neuf (3,9%) ont été testés positifs par ELISA pour l’anticorps du VHC, 7 (3,0%) ont été confirmés 
positifs par RNA PCR. Le taux de co – infection du VIH/VHB  a été 5,2%. L’infection aa été plus commun parmi les moins 
de 36 dans le cas de VHB et ceux âgés de plus de 36 dans le cas de VHC. Nous avons conclu que la prévalence de l’infection 
de VHB était élevée. L’étude était limitée par la conception transversale. 
 
     
93 
 
INTRODUCTION                                                              
Hepatitis B virus (HBV), Hepatitis C virus (HCV) 
and Human Immune Deficiency Virus (HIV) are 
among the top 10 leading causes of infectious 
disease deaths worldwide (1,2,3). Hepatitis B and C 
virus infections are frequent causes of chronic 
hepatitis worldwide and they create a significant 
burden to healthcare systems due to the high 
morbidity and mortality, and costs of treatment 
(4,5,6,7). 
Hepatitis B and C virus infections can cause chronic 
hepatitis, liver cirrhosis and hepatocellular 
carcinoma - all of which are of serious public health 
concern (4,6). Infection by HBV and HCV cause 
serious mortality, morbidity and place financial 
burden on patients and governments and are thus a 
major global health problem (8). Nigeria is a 
hyperendemic area of infection with both HBV and 
HCV which are major causes of both acute and 
chronic liver disease associated with the 
development of hepatocellular cancer.9These 
viruses share common routes of transmission, but 
they differ in efficiency by which certain types of 
exposures transmit them and in their prevalence by 
geographic region (10,11). 
 
The overall prevalence rate using the spot (rapid) 
test in a rural Ghana for HBV was highest in 2006 
(13.8%), but decreased in 2008 to 6.9%.12 However, 
the overall prevalence of HCV was highest in 2007 
(11.1%) but decreased to 7.0% in 2008 in the same 
rural community (12). 
Determining and monitoring the prevalence of viral 
hepatitis and its distribution in any community is 
useful for policy makers in order to formulate 
effective healthcare policies for patients with HBV, 
HCV and HIV infections(13). 
Based on anecdotal evidence there are few reports 
on the prevalence or co-infections of HBV and HCV 
in Jos metropolis. This study therefore is aimed at 
documenting the prevalence of these infections in 
subjects accessing HIV counseling and testing 
(HCT) at JUTH. 
 
The aim and specific objectives of this study was to 
determine the sero-prevalence of HBV and HCV 
infection among HCT subjects at JUTH using the 
ELISA method of assay. Also to determine the 
serum viral load of HBV, HCV and confirm 
identified seropositive samples using the PCR 
method. 
 
MATERIALS                                                                     
The study subjects were recruited from the HCT 
clients coming to JUTH, Jos for services. The JUTH 
HCT clinic attends to clients who voluntarily come 
for HIV counseling and testing on a daily basis.  
Subjects 18 years and above were recruited 
consecutively at the HCT unit of APIN JUTH. The 
HCT unit offers a continuing enrolment for 
volunteer clients who are 18 years or older into the 
ARV treatment programme. The HIV status of each 
subject was obtained from the clinic register. 
The total number of subjects enrolled was obtained 
by using the standard statistical formula for 
calculating sample size.14,15 Blood samples obtained 
from 232 HCT subjects were used for this study. 
 
All subjects starting from 18 years of age and above 
were included, these subjects were Antiretroviral 
drug (ARV) naive subjects. Only subjects who 
satisfied these criteria and accepted to join by 
signing the study consent form were included.  
 
METHODS 
About 5mls of blood was collected from each study 
subject into sterile plastic vacutainer with 
EDTA(16). Plasma was obtained from the whole 
blood by centrifugation at 1,500 RPM for 10 
minutes. This was separated into 2 vials and kept in 
a -20˚C refrigerator until use. The laboratory 
evaluation on blood sample obtained from each of 
the 232 subjects as well as kit reagent positive and 
negative controls supplied by the kit manufacturer 
was performed.The Hepatitis B Surface Antigen 
(HBsAg),antibody to HCV (antiHCV) as well as 
Viral load (PCR)resultswas recorded on each 
individual’s report form.  
 
The Epi Info 3.5.1 (CDC Atlanta, USA) statistical 
software was used for data analysis. Continuous 
variables with normal distribution were expressed 
as means with standard deviations. For continuous 
and skewed variables, median value with ranges 
was stated. The chi-squared test was used to 
determine significance of association between 
categorical variables. Where the cell frequency is <5, 
Fisher’s exact test was applied. Where more than 
two groups are being compared, ANOVA was 
used. P values of <0.05 was considered statistically 
significant. 
 
Ethical clearance for this study was obtained from 
the Jos University Teaching Hospital Ethics 
Committee.  
A consent form was signed by each subject who 
accepted to participate in the study. It was made 
clear to each subject that he/she was free to opt out 
from the study at any time without any prejudice to 
their care. 
All subjects benefited from this study by having 
their results disclosed to them in confidence. Those 
found to be infected with HBV or HCV were 
referred to a Consultant Physician for specialist 
management. 
 
RESULTS                                                                                                             
Of the 36 (15.5%) who tested positive for HBsAg by 
ELISA, 31 (86.1%) samples were confirmed positive 
by DNA PCR giving a concordance rate of 
86.1%.Among the 9 (3.9%) who tested HCV 
antibody positive by ELISA, 7 (77.8%) were 
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confirmed positive by RNA PCR giving a 
concordance rate of 77.8%).(Figure 1) 
The median HBV viral load count was 282 with a 
range of 0 to 413x106 counts per millilitre. The 
median HCV viral load count was 12.68x104 with a 
range of 0 to 1142x104(Table 1). 
A total of 36 (15.5%) subjects were found to HBV 
positive, 13 (5.6%) were male and 23 (9.9%) were 
females. A total of 9 (3.9%) were found to be HCV 
positive, 4 (1.7%) were males and 5 (2.2%) were 
female. Among the female subjects 23 (17.4%) and 
among the male subjects 13 (13.0%) tested positive 
for HBV.  
 
FIGURE 1: SERO-PREVALENCE OF HBV AND HCV 
BY BOTH ELISA AND DNA PCR AMONG ALL THE 
SUBJECTS STUDIED. 






IU/ml log /ml 
1 Positive* Not 
Detected* 
- 
2 Positive 49140.9 5.5 
3 Positive 1962199.3 7.1 
4 Positive 21786.9 5.1 
5 Positive 11821.3 4.8 
6 Positive 3333.3 4.3 
7 Positive 324054.9 6.3 
8 Positive 250171.8 6.2 
9 Positive* Not 
Detected* 
- 
Positive ELISA, Positive HCV RNA = Acute or Chronic 
HCV depending on clinical context.                                                                  
*Positive ELISA, Negative HCV RNA = Resolution of 
HCV; Acute HCV during period of low viraemia. 
 
DISCUSSION 
The prevalence of HBV infection among the HCT 
subjects studied was 15.5% by ELISA and 13.4% by 
DNA PCR. This difference of 2.1% in favour of 
virologic result, seem to indicate the virologic end 
point of HBV infection (i.e., a log10 reduction in the 
HBV DNA level or suppression of HBV DNA to an 
undetectable level [<10 to 100 IU per milliliter] (17).  
 
From our study, HBV prevalence from this high 
risk group for HBV and HCV infections is much 
higher than the findings in Ogbomosho(18) among 
pre degree science students of a higher institution 
and in Nassarawa state (19) in two rural 
communities in 2010. The result of the present 
study is similar to the findings in 2007,8 among 
male seminary student subjects of Jos and in 2011,20 
among blood donors in Jos. This study involved 
both sexes as subjects, but gave a similar HBsAg 
prevalence rate as other studies from Jos that were 
male dominated (20,21). 
 
The diagnosis of chronic HCV infection generally 
requires testing of serum for both antibody to HCV 
(anti-HCV) and for HCV RNA. (22). These two 
markers of HCV infection may be present in 
varying permutations in patients, requiring careful 
analysis for interpretation (22). In this study, the 
prevalence of HCV is 3.0% by PCR RNA, our 
concordance rate (77.8%), compares well with the 
concordance of studies from other parts of the 
world (23,24) and is consistent with the WHO 
estimated HCV prevalence of 2.2% - 3.0%.26,27 This 
HCV prevalence however, is low compared with 
previous findings reported from Jos by Egesie et al28 
in 2011 and Egah et al (29) in 2004 both studies were 
done among blood donors. HCV prevalence 
findings from other parts of the country (30,31) 
including report on blood donors from three 
hospitals in Kaduna state (32) in 2012; and report on 
blood donors from Lagos state (33)  in 2006 were all 
higher than our findings.  
 
Conclusion 
The prevalence of HBV and HCV infection by 
ELISA and by DNA PCR among HCT clients in 
JUTH was determined to be high. The infection was 
substantial among the study population especially 
in those younger than 37 years in the case of HBV 
and those older than 36 years in the case of HCV. 
  
Recommendations 
Hospital authorities should invest more in the 
training of Physicians in the use of molecular 
diagnostic methods fora more effective monitoring 
of infectious diseases. It is only the use of PCR in 
screening that would identify infected subjects in 
their window period; this has implications for 
blood transfusion and tissue transplant 
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patients in the management of HBV, HCV and HIV 
infected patients. Promotion of HBV screening and 
vaccination in the general population and 
continuation of HBV vaccination of children as part 
of the expanded programme on immunization 
should be encouraged. 
 
This study was limited by the cross sectional design 
- a direct observation of the sero-prevalence of 
HBsAg and HCV only; the implication of the effect 
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